Ketamine is a medication primarily used for starting and maintaining anesthesia. It is often used in medical settings such as hospitals and clinics for procedures or surgeries, particularly in emergency situations due to its rapid onset of action. Additionally, ketamine has gained attention for its off-label use in treating depression, PTSD, and certain chronic pain conditions.

Ketamine works primarily by antagonize (inhibit) the NMDA (N-methyl-D-aspartate) receptor in the brain. This receptor is involved in the transmission of signals related to perception of pain, emotions, learning, and memory. By blocking the NMDA receptor, ketamine reduces the transmission of certain neurotransmitters, particularly glutamate, which is involved in excitatory signaling, facilitating the release of neurotransmitters to transmit information between neurons.

The exact mechanism by which ketamine produces its anesthetic and analgesic effects is not fully understood, but it's believed to involve modulation of various neurotransmitter systems, including glutamate, dopamine, and serotonin. Additionally, ketamine may influence other receptors and pathways in the brain, contributing to its diverse effects.

In the context of its potential antidepressant effects, ketamine's impact on glutamate transmission and its ability to promote synaptic plasticity (the ability of neurons to change and adapt) are thought to play a key role. This may lead to rapid and sustained improvement in mood and other symptoms of depression, although further research is needed to fully elucidate the underlying mechanisms.

Patients who typically respond best to ketamine therapy for depression are those who have not experienced significant relief from traditional antidepressant medications or psychotherapy. This often includes individuals with treatment-resistant depression (TRD), which is characterized by a lack of response to multiple antidepressant treatments.

Additionally, ketamine therapy may be particularly beneficial for individuals experiencing severe depressive symptoms, including suicidal ideation or persistent feelings of hopelessness. Its rapid onset of action, often within hours to days compared to weeks for traditional antidepressants, can make it a valuable option for those in urgent need of relief.

However, it's important to note that not all patients will respond to ketamine therapy, and its long-term effectiveness and safety are still being studied. Factors such as the underlying cause of depression, comorbidities, and individual differences in response to ketamine can all influence its efficacy in a given patient. Therefore, treatment decisions should be made in consultation with a qualified healthcare provider who can assess each patient's unique situation and recommend the most appropriate course of action.

In addition to its biochemical effects, ketamine can also be utilized in a psycholytic capacity, which enhances its therapeutic potential for depression. At lower doses, ketamine induces a state of deep introspection and emotional openness, allowing patients to explore unresolved traumas, entrenched thought patterns, and repressed emotions more freely. This altered state can facilitate breakthroughs in psychotherapy by helping patients access and process difficult emotions in a controlled and supportive setting. Psycholytic ketamine therapy, when combined with skilled therapeutic guidance, enables deeper psychological healing, fostering long-term emotional growth and relief alongside its rapid mood-lifting effects.

At lower doses, ketamine can facilitate a psycholytic experience, where patients remain conscious and able to reflect on emotions and thought patterns, making it easier to process unresolved trauma or negative thinking.

As the dose increases, the experience can become more dissociative, leading to altered perceptions, a sense of boundary dissolution, and heightened awareness of inner mental states. These higher-dose psychedelic effects offer a unique therapeutic window, allowing for deep emotional and psychological breakthroughs in a safe, controlled setting.

The higher the dose of ketamine, the more likely you are to experience ketamine’s dissociative sensations and psychedelic effects.

Relaxation from ordinary concerns and usual states of mind, while maintaining conscious awareness of the flow of mind, is characteristic. Being under the influence of ketamine can lead to a disruption of negative feelings and obsessional preoccupations.

Ketamine creates an unusual experience of formlessness and a dissolving of boundaries and has novel effects on the mind.

The psychedelic and dissociative effects of ketamine are short-lived, and most people return to their ordinary level of awareness and state of mind within 45-60 minutes following administration.

Risks vary between low and high doses of ketamine.

The higher the dose, the increased risk of disorientation issues including temporary lack of spatial or temporal awareness, loss of recognition of environment or self, and/or loss of coordination or balance.

Typically, ketamine causes a significant increase in blood pressure. This can sometimes be mitigated through blood pressure medication.

At extremely high dosages, ketamine can cause adverse effects that include hypoxia, apnea, hypotension, dysphoria, and dysrhythmia.

Potential side effects will be discussed in more detail in your Psychiatric Evaluation & Medical Screening.

Before participating in KAP, you will be carefully screened to determine whether KAP is an appropriate and safe treatment for your medical condition.

Screening may include a medical history, a physical exam including bloodwork if deemed necessary, review of your medical/psychiatric records, and psychiatric history.

While information on ketamine’s interaction with other medicines is only partially available, screening will assess various indications and contraindications for ketamine in the context of your physical, psychological and pharmacological history and presentation.

We reserve the right based on our medical and clinical judgment to determine if you eligible for KAP or excluded from this treatment.

Pregnant women and nursing mothers are not eligible for ketamine treatment.

Contraindications that require further evaluation to determine severity and treatment to move forward with treatment include:

-Untreated hypertension

-History of heart disease

-Untreated hyperthyroidis

-Active mania

-Active suicidality

-Active Psychosis

-Alcohol or substance use disorders in which cessation for treatment would risk severe withdrawal symptoms

-History of severe dissociation

-Severe personality disorders